Introduction
At least 20% (range 20 ± 60%) of human and neck squamous cell carcinomas (HNSCC) have amplification of genes that localize to 11q13 (Rubin et al., 1995; Lammie and Peters, 1991) . The presence of 11q13 ampli®cation portends a poor prognosis (Akervall et al., 1995; Michalides et al., 1995) . This ampli®cation also occurs frequently in esophageal (Tsuda et al., 1989) , breast (Dickson et al., 1995) , and bladder tumors (Bringuier et al., 1996) . The region contains many growth regulatory genes implicated in tumorigenesis, including CCND1 (cyclin D1) (Inaba et al., 1992) . CCND1, as well as other genes in this region can be, but are often not, overexpressed in tumors with 11q13 ampli®cation (Gaey et al., 1995) .
The murine region syntenic to most of the 11q13 amplicon is located in the telomeric portion of Chr 7 . Mouse Chr 7 contains Fgf4 and Fgf3 loci that are separated by 17 kb with Fgf3 being more telomeric . Ccnd1 is located in the same region 75 kb centromeric to Fgf4 (Lammie et al., 1992; Bianchi et al., 1993a) . The human amplicon is approximately 50 kb larger than the syntenic region on mouse Chr 7 with the genes having the same orientation (Lammie and Peters, 1991) . A portion of the 11q13 amplicon is also syntenic with the centromeric region of murine Chr 19. Ccnd1 is ampli®ed in approximately 15% of 7,12-dimethylbenz(a)anthracene) (DMBA)/12-O-tetradecanoylphorbol 13-acetate (TPA)-induced murine squamous cell carcinomas (SCC) (Bianchi et al., 1993a) while cyclin D1 overexpression is detected in most tumors (Bianchi et al., 1993a; Robles and Conti, 1993) .
In contrast to Ccnd1 ampli®cation, other mutations initiated by chemical carcinogenesis in murine squamous cells frequently occur on Chr 7. Point mutations at Hras1 occur in 60 to 95% of skin tumors (Balmain and Brown, 1988; Kemp et al., 1993; Bianchi et al., 1993b) . Loss of heterozygosity (LOH), trisomy and chromosomal non-disjunction involving Chr 7 frequently are detected in the late phases of DMBAinduced tumorigenesis (Bremner and Balmain, 1990; Bianchi et al., 1990 Bianchi et al., , 1991 Buchmann et al., 1991) . Hras1 activation appears to be associated with increased cyclin D1 expression (Filmus et al., 1994; Winston et al., 1996) . However, the incidence of Hras1 mutations and LOH on Chr 7 has not been correlated with Ccnd1 ampli®cation and cyclin D1 overexpression. In human HNSCC Hras1 mutations occur in no more than 10% of tumors (Rumsby et al., 1990; Clark et al., 1993) and the incidence of Hras1 mutations has not been reported in tumors with either 11q13 amplification or cyclin D1 overexpression.
We have shown that approximatley two thirds of 4-nitroquinoline (4NQO) induced murine oral cavity SCCs have HRAS1 point mutations (Yuan et al., 1994) . Half of the tumors with Hras1 mutations undergo LOH involving the distal half of mouse Chr 7 during 4NQO-induced squamous cell carcinomas (SCC) (Yuan et al., 1997) . This portion of the chromosome contains oncogenes, tumor suppressor genes, and growth regulatory genes including Hras1, H19, Igf2, Kip, as well as the region syntenic to a portion of 11q13. Since LOH occurs in the syntenic region of the chromosome that undergoes amplification in HNSCC (Lammie and Peters, 1991) we posited that the syntenic region might be similarly ampli®ed in 4NQO-induced murine HNSCC, that ampli®cation was associated with LOH, and that ampli®cation would lead to cyclin D1 overexpression. This report shows that the syntenic region is ampli®ed and ampli®cation is associated with LOH. Cyclin D1 overexpression, however, can occur without gene ampli®cation.
Results

Quantifying DNA
To determine if gene ampli®cation had occurred within the region syntenic to 11q13 in 4NQO-induced murine tumors we had to quantify the DNA that was extracted from the tumor. Since little tumor remained after our previous studies Yuan et al., 1994 Yuan et al., , 1997 , this was done using PCR based analysis. DNA was isolated from cryopreserved tissue sections that contained tumor and morphologically uninvolved tissues (Yuan et al., 1994) . To estimate DNA concentration known amounts of normal mouse liver DNA were simultaneously ampli®ed with unknown amounts of DNA from tumor specimens. Since LOH included the region of interest on Chr 7 was detected in one third of the 4NQO-induced tumors (Yuan et al., 1994 (Yuan et al., , 1997 , we were concerned that the process had signi®cantly altered the copy number of alleles since this region of the Chr 7 may be hemizygous in a tumor. Therefore, segments within Prp on Chr 6, a chromosome that did not undergo LOH, Ngfg at 21 cM on Chr 7, outside the region of LOH, and Th on Chr 7, within the region of LOH but 7 cM outside the region syntenic to the 11q13 amplicon (Yuan et al., 1997) , were ampli®ed to quantify the DNA present in the tissue specimens (Table 1) . A crude estimate of tumor DNA concentrations was determined using serial dilutions of liver DNA as external standards. In this analysis using Prp and Ngfg, the yield of each PCR ampli®cation depends on the initial DNA concentration when ampli®cation is exponential and was con®rmed with 1 and 20 ng of liver DNA ( Figure  1a and b) . The DNA concentration was estimated by comparison of the tumor DNA to known concentrations of mouse liver DNA ampli®ed in parallel (Gilliland et al., 1990) . Subsequently, all samples were diluted to an estimated concentration of 50 pg/ ml. This approach will not discriminate dierences in copy number of less than two (Gilliland et al., 1990) .
To more accurately determine the concentration of tumor DNA, segments within the Th loci were ampli®ed in a competitive PCR (Gilliland et al., 1990) . DNA that contained the same primer sites as those of the endogenous targets, but with a dierent template length, was added to the reaction mixture as an internal standard and co-ampli®ed ( Figure 1c) . A (GA) n (GT) n microsatellite in Th had been shown to be polymorphic in CBA/J liver and tumor DNA (Yuan et al., 1997) . The only two alleles detected diered by approximately 20 bases and their distribution in these tumors had been reported (Yuan et al., 1997) . When tumors were homozygous for the shorter allele, plasmid DNA, containing the longer Th allele, was used as an internal standard and, vice versa for co-ampli®cation. The products of the exogenous and endogenous templates were readily distinguished by gel electrophoresis and the relative ratio of ampli®ed products determined (Figure 1c ). Since the product ratio of the internal standard to target DNA did not vary during ampli®cation, PCR was carried out to saturation maximizing the assay's sensitivity. Using a series of standard DNA concentrations in simultaneous coampli®cations, the DNA concentration in the tumor samples was extrapolated by determining the equivalence point of the Th ampli®cation (Figure 1c ). This was veri®ed by repeating the ampli®cation using equivalent concentrations of tumor DNAs with the Prp and Ngfg primers (data not shown). The top sequence is the GenBank or reported primer sequence and the bottom is a complementary primer sequence 3' to the top sequence. ID: sequence identi®cation numbers were obtained from GenBank. Chr (cM): chromosome number and distance in centimorgans from the centromere (Love et al., 1990; Rinchik et al., 1992; Buchberg et al., 1992 
Gene ampli®cation
To determine if ampli®cation had occurred in the region syntenic to 11q13, segments within Fgf3 were similarly ampli®ed using competitive PCR. For this analysis D25, an Fgf3 ampli®ed segment with a 25 bp deletion between two EarI sites, was synthesized and cloned. Standard concentrations of cloned plasmid DNA containing the deletion (pFgf3CA 2 D25) were added to a constant amount of tumor DNA as determined in the previous experiments and co-ampli®ed with Fgf3 oligonucleotide primers. Four-to eightfold gene ampli®cation at Fgf3 was observed in ®ve tumors which had Hras1 mutations and had undergone LOH on Chr 7 (Figure 2a and b; Table 2 ). Tumor #21, which had neither an Hras1 mutation or LOH on Chr 7, appeared to have twofold ampli®cation (Figure 2c ). The other seven tumors without LOH had no evidence of ampli®cation. The DNA from tumors that were heterozygous at the Th locus could not be analysed using the competitive PCR assay. These were analysed using semi-quantitative PCR and the ampli®cations were compared with simultaneous ampli®cation of ®ve tumor DNAs that had been quanti®ed using competitive PCR. The semi-quantitative assay was consistent with the competitive assay when either ampli®cation was not detected or when the amplification exceeded twofold. However, the semi-quantitative assay did not detect the apparent twofold amplification in tumor #21 observed by competitive PCR. None of the tumors assayed using only the semiquantitative method had detectable Fgf3 ampli®cation ( Figure 3a ).
To determine if other genes within the region syntenic to 11q13 were ampli®ed, Ccnd1 and Fgf4 were analysed. Since the DNA that remained was limited, these loci were analysed using a semiquantitative assay (Figure 3b and c). At least two DNA samples from each tumor were ampli®ed independently, in duplicate, and all samples were ampli®ed in parallel with liver DNA standards of known concentrations. No signi®cant variation was observed among duplicate specimens in multiple reactions. The level of ampli®cation observed with semi-quantitative PCR at Fgf3, Ccnd1 and Fgf4 was identical to that observed with Fgf3 using the competitive PCR assay (compare Figures 2 and 3 ). That the presence or absence of gene ampli®cation was Estimation of tumor DNA concentrations using PCR. Genomic DNA was isolated from tumors (Yuan et al., 1994) . DNA was ampli®ed using Prp (a) and Ngfg (b) primers for 35 cycles. Known concentrations of mouse liver DNA were ampli®ed simultaneously in separate reactions as external standards. The ampli®ed product was identi®ed by electrophoresed in a 3% agarose containing 1 mg/ml ethidium bromide. Molecular weight standards (MW), a HaeIII digest of pBR322. (c) Quantifying tumor DNA using competitive PCR at the Th locus. All DNA samples analysed were homozygous at the Th locus. The cloned longer allele of Th was added to the ampli®cation mixture as an internal standard for all tumor DNA except #29 and #15 where the cloned shorter allele was added. Plasmid DNA containing 20, 80, 140 and 200 copies were added to ampli®cation mixtures containing a constant amount of tumor DNA as estimated by PCR (b). 10 ml of each PCR product was subjected to electrophoresis in a 3% agarose gel containing 1 mg/ml ethidium bromide. The numbers identify the tumor specimens as previously reported (Yuan et al., 1994 (Yuan et al., , 1997 . Arrowheads identify the equivalence points Hras1 mutations (Yuan et al., 1994) and LOH on Chr 7 (Yuan et al., 1997) as previously in 4NQO-induced tumors. *:allele with Hras1 mutation; + : wild type Hras1 allele; +: the presence of LOH. Gene ampli®cation was quanti®ed from analysis presented in Figure 2 . Cyclin D1 expression ( Figure 4 ) was semi-quantitative and graded.
7 : not detected; +: detected but not overexpressed; ++ to ++++: increased expressed; nd: not done consistent in the 18 specimens analysed indicates that ampli®cation involved the entire region between Fgf3 and Ccnd1.
Four-to eightfold gene ampli®cation was observed in ®ve of six tumors with Hras1 mutations and LOH at Chr 7 (Figure 2 ). The degree of ampli®cation was determined by comparison with the number of Th copies present. If the mechanism of LOH were deletion, then only a single copy of Th was present and the amount of ampli®cation detected in tumors with LOH would be doubled. The range of amplification would be 8 ± 16-fold. Gene ampli®cation was not detected in tumor #24 which had LOH on Chr 7. Only one tumor (tumor #21) that remained heterozygous at Hras1 and none of the tumors with wild type Hras1 had evidence of ampli®caiton. The ampli®cation in tumor #21 was not detected in the semi-quantitative assay using the same oligonucleotide primers speci®c for segments in Fgf3 or with primers which ampli®ed segments in the Ccnd1 and Fgf4. As this twofold ampli®cation was detected only using the competitive, more quantitative assay, this minimal ampli®cation may represent the accumulation of errors in the multiple reactions required for the analysis. Alternatively, the results obtained with the competitive assay were correct and the semi-quantitative assay lacked the sensitivity to discriminate twofold dierences. The tumor DNA available was insucient to repeat the quantitative analysis using Ccnd1 and Fgf4 primers. The incidence of ampli®cation in tumors with Hras1 and LOH when compared to those that remained heterozygous at Hras1 or had no Hras1 mutations was highly signi®cant (P=0.001; X 2 =13.8462; d.f.=2) (Systat 6.0, Evanston, IL 1994) .
Expression of cyclin D1
Conti's group observed that two of 13 DMBAinduced skin tumors had Ccnd1 ampli®cation (Bianchi et al., 1993a) , while most tumors over- expressed cyclin D1 (Bianchi et al., 1993a; Robles and Conti, 1993) . To compare cyclin D1 expression with ampli®cation, cyclin D1 was assayed using a polyclonal rabbit antibody (Robles and Conti, 1993) which speci®cally recognizes murine cyclin D1 ( Figure  4 ). Similar analysis with HD-11 and 72-13G, rat antimurine cyclin D1 monoclonal antibodies (Santa Cruz Biotechnology, Santa Cruz CA) had signi®cant background binding which could not be eectively blocked (data not shown). The ®ve tumors with gene ampli®cation at Ccnd1 as well as six tumors without gene ampli®cation were analysed (Table 2) . Tumor #21, the tumor with twofold ampli®cation and no LOH, could not be evaluated because the entire tumor had been used in the earlier assays. Tumor #30, with eightfold ampli®cation and tumor #9, which was heterozygous at Hras1 and with no ampli®cation, had increased cyclin D1 expression (Figure 4 ). Cyclin D1 was not overexpressed in all other tumors analysed. Thus, cyclin D1 expression was independent of the level of gene ampli®cation and was not associated with LOH. Although most tumors with Hras1 mutations did not overexpress cyclin D1, both tumors with cyclin D1 overexpression were mutated at Hras1. Thus, it is possible that Hras1 mutations may be required for overexpression in 4NQO-induced tumors. Cyclin D1 was not signi®cantly overexpressed in either normal tongue or metaplastic tissue surrounding either of the tumors with increased cyclin D1 (Figure 4 ).
Discussion
7F4 Gene ampli®cation frequently occurs in inbred CBA/ J mice Ccnd1 had been previously shown to be occasionally ampli®ed in DMBA/TPA-induced murine skin SCC (Bianchi et al., 1993a) . The present report demonstrates that in 4NQO-induced oral cavity squamous carcinogenesis, not only is Ccnd1 consistently ampli®ed but the region extends from Ccnd1 to Fgf3. These results suggest that 11q13 and the syntenic murine region on Chr 7 (7F4 amplicon) are both amplicons. This is the ®rst report of syntenic regions in human and mouse chromosomes undergoing ampli®cation during tumorigenesis. Furthermore, in 4NQO-induced SCC the ampli®cation frequency is similar to that observed in human neoplasms and in particular, HNSCC. Gene ampli®cation in inbred CBA/J mice appears to be associated with LOH and Hras1 mutations Carcinogen-induced murine SCCs frequently develop Hras1 mutations which undergo LOH involving the distal portion of Chr 7 regardless of the carcinogen, the site of the tumor, or the genetic background of the mouse. The relationship of these events with amplification has not been previously addressed. The present study of CBA/J mice demonstrated a highly signi®cant coexistence of these molecular events with 7F4 ampli®cation. Extrapolating from the reported 90% incidence of Hras1 mutations induced by DMBA/TPA (Bianchi et al., 1990) , the 70% incidence of LOH (Bianchi et al., 1991) and the less than 20% incidence of Ccnd1 ampli®cation (Bianchi et al., 1993a) in tumors suggests that these events are independent in outbred SENCAR mice. Gross chromosomal events including LOH on Chr 7 are restricted to tumors that have Hras1 mutations (Bremner and Balmain, 1990; Bianchi et al., 1990; Buchmann et al., 1991; Bremner et al., 1994; Yuan et al., 1994 Yuan et al., , 1997 . Since gene ampli®cation was only detected in both models of squamous carcinogenesis after carcinogen exposure has ceased, it is our presumption that the ampli®cation is not due to dierences in the carcinogen application or action. In DMBA-treated outbred SENCAR and F1 mice that develop skin SCC, the intermediate events can include deletion, mitotic recombination, trisomy and chromosomal non-disjunction (Bianchi et al., 1990; Buchmann et al., 1991) . Whereas in 4NQO-induced oral cavity SCC, LOH occurs only through either deletion or mitotic recombination (Yuan et al., 1997) . However, trisomy of Chr 7 was detected in all of the SENCAR mice in which Ccnd1 was not ampli®ed (Bianchi et al., 1993a) . Since 7F4 amplicon ampli®cation occurs more frequently in 4NQO than in DMBA-induced skin tumors (P50.0001), it is our speculation that 4NQO-induced tumors develop ampli®cation as a result of the gross chromosomal event which lead to LOH involving Hras1 by means of deletion or mitotic recombination. Loss of the wild type Hras1 allele results in unopposed mutant activated p21 that could potentially lead to gene ampli®cation. Stambrook's group has demonstrated that 20-fold overexpression of a transfected mutant Hras1 can rapidly induce gross chromosomal degeneration and gene ampli®cation (Denko et al., 1994; Wani et al., 1994) . Since the introduction of an activating point mutation into Hras1 is not sucient to transform rat cells (Finney and Bishop, 1993) , it is unlikely that the loss of the wild type Hras1 allele, in itself can result in a dosage eect which leads to ampli®cation.
LOH on Chr 7 could have resulted in the loss or decreased expression of a tumor suppressor gene(s) which might have aected DNA repair, progression through the cell cycle, or apoptosis. These regulators either acting in concert or independently might allow ampli®cation and/or result in a mutator phenotype leading to genomic instability. This speculation is supported by our preliminary observations: tumors with 7F4 ampli®cation also have deletion or mitotic recombination on Chr 11 (Lentsch et al., manuscript in preparation) and only in tumors with gene amplification have multiple new segments identi®ed by DNA ®ngerprint and sequence analysis (Hu et al., 1995) .
However, since DMBA-induced SCC are infrequently associated with 7F4 ampli®cation, LOH is not the critical event. Ampli®cation could have also developed as a direct consequence of gross chromosomal events, such as deletion, mitotic recombination or chromosomal non-disjunction that result in LOH (a cis eect). Since the incidence of ampli®cation was signi®cantly higher in inbred mice, the lack of genetic diversity in the CBA/J mice may have aected the incidence of ampli®cation.
Possible mechanisms by which LOH and ampli®cation occur
4NQO-induced tumors with Hras1 mutations and LOH have either undergone deletion or mitotic recombination. The gene copy number detected with the probes for Ngfg and Th, loci on Chr 7 that lay outside and within the region of LOH, appear to be equivalent. This suggests that LOH involves mitotic recombination and not deletion. However, these data are far from conclusive since the analysis probably can not accurately discriminate between one and two copies of an allele.
Since 7F4 represents the most telomeric region on Chr 7, an attractive model for ampli®cation during LOH would be the addition of the 7F4 amplicon from the lost chromosomal region to the Chr 7 that is retained. LOH on Chr 7 appears to include loss of all alleles from a region telomeric to Tyr to the telomere including the 7F4 amplicon (Yuan et al., 1997) . Since LOH occurred at Fgf3, ampli®cation must have involved only the Fgf3 allele that was retained during LOH; i.e., ampli®cation involved only the Chr 7 with the Hras1 mutation. Therefore, either chromosomal or episomal ampli®cation developed using the remaining 7F4 amplicon as template. The lone human study addressing the relationship of LOH and 11q13 ampli®cation found the opposite relationship (Foulkes et al., 1993) . Four of four tumors with ampli®cation at 11q13 maintained heterozygosity at FGF3 while apparently undergoing LOH at 11q22-ter. The region of LOH did not apparently include 11q13. Alternatively, LOH at region centromeric to 11q22 would have been missed if the region containing FGF3 were added to the`normal' Chr 11 and ampli®ed.
Cyclin D1 expression is independent of Ccnd1 ampli®cation and Hras1 activation Cyclin D1 expression does not correlate with Ccnd1 gene ampli®cation in 4NQO or DMBA-treated mice. The incidence of cyclin D1 overexpression is very low in CBA/J when compared to SENCAR mice. The observations in 4NQO-induced tumors are similar to that observed in human tumors where typically no more than 50% of tumors with ampli®cation in this region have increased cyclin D1 expression (Gillett et al., 1994; Gaey et al., 1995) . Hras1 mutations are relatively rare in human tumors, no correlation exists with cyclin D1 overexpression. Cyclin D1 overexpression can occur in human tumors with the absence of ampli®cation as well (Gillett et al., 1994) . Although Conti's group analysed Ccnd1 DNA and PCNA expression in one set of tumors (Bianchi 1993a ) and cyclin D1 protein expression in a second set (Robles and Conti, 1993) , the implication is that overexpression had occurred in tumors with and without Ccnd1 ampli®cation.
Hras1 activation appears to be associated with cyclin D1 expression in cultured rodent cells (Filmus et al., 1994; Winston et al., 1996) . Since most DMBA-induced skin tumors have Hras1 mutations (Bianchi et al., 1990) , this association has probably been observed in tumors as well (Bianchi et al., 1993a) . However, in the 4NQO-induced tumors no association between Hras1 and cyclin D1 expression was detected and cyclin D1 overexpression was rare. Conti's group has attributed the increased cyclin D1 expression as a response to exposure to the promoter, TPA (Bianchi et al., 1993a) . Since the 4NQO-treated mice were not exposed to a promoter, this may explain the observed absence of cyclin D1 expression.
The temporal relationship of Hras1 mutations, LOH and gene ampli®cation during tumorigenesis
Chemical carcinogens cause mutations through DNA adduct formation resulting in Hras1 mutations (Quintanilla et al., 1986; Bremner and Balmain, 1990; Bianchi et al., 1991; Yuan et al., 1994) . 4NQO-treatment of the oral cavity was relatively short and LOH and ampli®cation were only detected in late tumors with Hras1 mutations. In murine skin carcinogenesis LOH at Hbb and Fgf3 (Bremner and Balmain, 1990; Bianchi et al., 1991) occurs during the conversion step from late papillomas to SCCs. Cyclin D1 overexpression as well as gene ampli®cation has been associated with the conversion of papillomas to SCC after the cessation of exposure to the carcinogen (Bianchi et al., 1993a) . Thus, ampli®cation did not develop as a direct consequence of exposure. The presumption is that gene ampli®cation occurs subsequent to LOH because one 4NQO-induced tumor had LOH without gene ampli®cation. Our preliminary data suggest that other gross chromosomal events have occurred as well on Chr 11 and presumably result from genomic instability. These tumors may be developing a mutator phenotype.
It is important to emphasize that only two-thirds of the 4NQO-induced SCC have Hras1 mutations, and only half of these undergo LOH and gene amplification. Therefore, only one third have Hras1 mutations, LOH, and gene ampli®cation. Neoplastic transformation and tumorigenesis must occur by alternative pathways which may or may not involve Hras1 mutations and in which LOH and gene ampli®cation on Chr 7 do not occur.
Comparison of the ampli®cation in murine and human malignancies 4NQO-induced tumors had 4 ± 8-fold which is modest in comparison with what has been observed in human tumors. However, the murine tumors were no larger than 5 mm with no nodal metastasis , whereas most human tumors with ampli®cation are very large lesions and associated with lymph nodal metastasis.
In contrast to murine carcinogenesis, there is little reason to suspect in human tumors an association of Hras1 mutations, LOH at Chr 11p15 or 11q22-ter, and 11q13 ampli®cation. Hras1 mutations occur in no more than 10% of HNSCC and other malignancies with frequent 11q13 ampli®cation. Oral cavity lesions developing among tobacco chewers are the one exception where the incidence may approach 60% and half of these tumors are associated with 11p15 LOH (Saranath et al., 1991b; Huber et al., 1996) . 11q13 ampli®cation has not as yet been studied in these tumors. Hras1 point mutations and LOH at 11p15 have been reported in many human tumors (Fearon et al., 1984 (Fearon et al., , 1985 Ali et al., 1987; Srivatsan et al., 1991; Howell et al., 1989; Saranath et al., 1991a; Riou et al., 1988; Viel et al., 1991; Gustafson et al., 1994; Huber et al., 1996) , but again 11q13 ampli®cation was not evaluated in these tumors.
Gene ampli®cation at 11q13 frequently occurs (Tsuda et al., 1989; Somers et al., 1990; Lammie and Peters, 1991; Hinds et al., 1994) and may be as frequent as 60% in HNSCC (Rubin et al., 1995) . Since Hras1 point mutations are rarely detected in HNSCC among western populations (Rumsby et al., 1990; Clark et al., 1993; Michalides et al., 1995) , 11q13 ampli®cation must occur in the absence of Hras1 mutations. These observations do not preclude the possibility that tumors with Hras1 mutations and/or LOH at 11p or 11q are associated with 11q13 ampli®cation. Since the Hras1 focus is at 11p15.5 and the amplicon is at 11q13, separation of these loci by the centromere should prevent overlapping LOH from occurring. In human breast carcinomas, presumably without Hras1 mutations, LOH at 11p15 and l1q22-23 are frequent but apparently independent events (Carter et al., 1994) . In one study of ovarian cancer probably all of the tumors with 11q13 ampli®cation (four of 28) had LOH at 11q22-23, but an equal number of tumors with LOH did not have 11q13 ampli®cation (Foulkes et al., 1993) .
The 7F4 amplicon is in the most telomeric region of mouse Chr 7. LOH in murine carcinogenesis universally involves the telomeric half of Chr 7. The linkage with ampli®cation in inbred mice would suggest that the process by which LOH occurs either allows or causes the ampli®cation. Since ampli®cation occurs in 11q13, in the middle of the 11q arm, and apparently in the absence of LOH and Hras1 mutations, this would suggest that the LOH may have little to do with the ampli®cation. 11q13 ampli®cation may be due to fragile sites which¯ank the amplicon (Coquelle et al., 1997) . It is our speculation that the 7F4 amplicon contains homologous ampli®cation prone elements.
The role of the 11q13/7F4 amplicon in tumorigenesis
Mutations of growth regulatory genes may lead to multiple subsequent gross genetic events (Hartwell and Kastan, 1994; Hinds et al., 1994; Denko et al., 1994) . Overexpression of cyclin D1 dramatically shortened the G1/S transition, presumably preventing apoptosis and enabling cells with damaged DNA to enter S phase more rapidly and accumulate genetic defects (Quelle et al., 1993) . However, ampli®cation of CCND1/Ccnd1, in human and murine tumors does not always lead to cyclin D1 overexpression (Gillett et al., 1994; Gaey et al., 1995) . Ampli®cation of 11q13 could result in overexpression of other regulatory genes in this region. Although this has been considered since 11q13 ampli®cation was ®rst identi®ed (Winqvist et al., 1993) , overexpression of other genes within the region has been inconsistently observed.
In tumors with 7F4 ampli®cation but without cyclin D1 overexpression, cyclin D1 plays no role in tumorigenesis. The murine 7F4 amplicon contains other important regulatory genes, including Fgf3 and Fgf4, and possibly Men1 and Ems1 for which the murine loci have not as yet been identi®ed. Until expression or loss of expression of other important regulatory genes are demonstrated, the role of the amplicon in transformation remains an enigma. Thus, ampli®cation without cyclin D1 expression may be a tumor associated event not aecting tumorigenesis, i.e., a marker of genomic instability.
Materials and methods
4NQO-Induced oral cavity tumors
CBA/J mice were exposed to 4NQO for 4 to 16 weeks . SCC developed in the oral cavity at least 6 months after exposure to the carcinogen had ceased. These tumors have been previously evaluated for mutations and LOH at Hras1 (Yuan et al., 1994) , and the region on Chr 7 at which LOH occurred (Yuan et al., 1997) . For this report 18 specimens were selected from tumors with no Hras1 mutations (n=6), tumors heterozygous for mutant Hras1 at codon 12 (n=6), and tumors with LOH at Hras1 (n=6). The tumors as well as their normal livers had been frozen in liquid N 2 and stored at 7708C.
Determination of DNA concentration
DNA was isolated from mouse liver using standard techniques (Yuan et al., 1994) . The concentration was determined by u.v. spectroscopy. The DNA was diluted (20 pg/ml, 200 pg/ml, 2 ng/ml and 20 ng/ml) and used as external standards in subsequent ampli®cation reactions. Cryopreserved tissues containing SCC were sectioned (6 ± 8 mm) and tumor tissues were dissectd (Yuan et al., 1994) . Tumor DNA from ®ve to 10 sections was solubilized with 100 ml of (0.5% NP-40 w/v (Sigma, St. Louis MO), 10 mM Tris-HCl (pH 8.0), 10 mM NaCl, 3 mM MgCl 2 , 0.5% sodium dodecyl sulfate). Since the amount of DNA isolated from the tissue sections could not be determined by u.v. spectroscopy, the DNA concentration was crudely estimated by comparing the ampli®cation of mouse liver DNA with 5 ml of tumor DNA using oligonucleotide primers for segments within Prp and Ngfg (Table 1) . Each ampli®cation was carried out independently in duplicate and in parallel using the same master solutions for 35 cycles. The ampli®ed products (10 ml) were characterized by electrophoresis on 2% agarose/TBE gels. Using serial dilutions of liver DNA, the range of ampli®cation cycles during which exponential accumulation occurred was determined. The ampli®ed products generated from each tumor specimen were compared to the ampli®ed products of the mouse liver DNA and the DNA concentration of the tumor specimen extrapolated. The tumor DNA concentration was adjusted to 50 pg/ml.
To more accurately estimate the DNA concentration in the solutions from tumor specimens, competitive PCR was carried out (Gilliland et al., 1990) . Two allelic variants of a microsatellite repeat within the tyrosine hydroxylase (Th) gene of CBA/J mice which had been previously identi®ed were used as internal controls. The allelic variants had been isolated and cloned into the pCR TM II plasmid (Invitrogen, Irvine CA). Since tumors #3, 4, 5, 9, 11, 12, 21, 24, 27 and 30 were homozygous for the shorter allele, the plasmid containing the longer Th allele was added to the reaction mixture as an internal standard. In reactions with tumors #15 and 29, homozygous for the longer allele, and tumors #10 and 26 which had lost the shorter allele during tumorigenesis (Yuan et al., 1997) , the plasmid containing the shorter Th allele was added as the internal standard. Since tumors #14, 22, 23 and 28 remained heterozygous during tumorigenesis, the DNA concentration could not be determined using competitive PCR with Th alleles. Five microliters of tumor DNA, containing either 20 or 50 pg (approximatley 100 or 250 copies) (Cha et al., 1992) , were pipetted into 4 tubes that contained 30 ml of a PCR master solution (1.256Taq buer, 250 mM dNTP, 1.25 mM of each primers) and 5 ml of plasmid DNA with 20, 80, 140 and 200 copies, respectively. Mineral oil (30 ml) was added and a`hot start' was carried out (958C for 1.5 min with the subsequent addition of 10 ml of 16Taq buer with 1.25 U of Taq polymerase). Ampli®cation continued for 45 cycles. The PCR products was analysed on 2% agarose/0.56TBE gels containing 1 mg/ml ethidium bromide. The concentration of DNA was extrapolated from the equivalence point, i.e. where the ampli®ed product from the tumor DNA and the plasmid DNA were equal. The concentration of DNA was veri®ed by a second independent ampli®cation of tumor DNA using equivalent concentrations. The concentration of DNA extracted from tumors that were not polymorphic at Th was estimated by comparing the ampli®ed products generated with oligonucleotide primers for Prp and Ngfg with that obtained with standard concentrations of liver DNA.
Construction of an Fgf3 DNA segment with a deletion
A 261 bp region of the murine Fgf3 gene was ampli®ed by PCR using speci®c oligonucleotide primers (Table 1) , ligated, and cloned into pCR TM II (pFgf3CA 2 ) (Figure 4) . pFGF3CA 2 DNA (10 mg) was digested with ®ve units of EarI in 16 buer M (USB, Clevland OH) at 378C for 2 h to delete a 25 bp segment. The 25 bp fragment was removed by centrifugation through a Chroma Spin-100 gel matrix (Clonetech, Palo Alto CA). The resulting linear DNA was ligated and transformed. The cloned plasmid DNA (pFGf3CA 2 D25) was ampli®ed by PCR and the deletion (D25) veri®ed by EarI digestion. The pFgf3CA 2 D25 DNA concentration was determined by u.v. spectroscopy and used as an internal standard for competitive PCR.
Quantifying gene ampli®cation at the Fgf3 amplicon by competitive PCR An estimated 100 copies of tumor DNA in 5 ml was ampli®ed with 30 ml of the PCR master solution, and mixed with 5 ml of pFgf3CA 2 D25 DNA. Sucient DNA from tumors #9, 11, 12, 21, 27 and 29 was available for three PCR ampli®cations, using 100, 200 and 400 copies of pFgf3CA 2 D25 as internal standards. Tumors #3, 5, 4, 15, 24, 10, 26 and 30 were co-ampli®ed in ®ve reaction mixtures with 100, 200, 400, 800 and 1000 copies of pFgf3CA 2 D25. After a hot start, the templates were ampli®ed for 45 cycles. The ampli®ed products (10 ml) were evaluated on 3% agarose gels containing 10 ng/ml ethidium bromide. The tumor DNA concentration was interpolated from the equivalence point where the ampli®cation from the DNA and the plasmid DNA were equal.
Detection of co-ampli®cation at the Fgf3 amplicon by semiquantitative PCR To determine if other nearby genes were similarly ampli®ed, the DNA copy number for Fgf3, Fgf4. and Ccnd1 were compared using semi-quantitative PCR. Tumor DNA (250 pg) was ampli®ed with Fgf3, Fgf4, and Ccnd1 oligonucleotide primers (Table 1) at 948C, 658C, and 728C for 1 min for 35 cycles. Mouse liver DNA (0.2, 0.5 and 1 ng/5 ml) was ampli®ed simultaneously as external standards. Ten microliters of the ampli®ed products were subjected to electrophoresis on 2% agarose gels. The amount of product present was estimated by comparisons with that ampli®ed from liver DNA standards. To verify the assay's internal consistency, the semi-quantitative PCR ampli®cation was repeated with duplicate samples under identical conditions.
Immunohistochemical analysis of cyclin D1 expression
Cryopreserved tissue sections (6 to 8 mm) from 12 tumors, normal mouse tongue, and CH72 cells (a gift of Dr Claudio Conti, Science Park, UT MD Anderson Cancer Center, Smithville TX) were ®xed with 50% acetonephosphate buered saline (PBS) for 30 min, washed with PBS, and incubated with a polyclonal rabbit anti-mouse cyclin D1 antibody (UBI, Saranac NY) for 18 h at 48C. The sections were washed three times with PBS. Antibody was detected with biotinylated conjugated second antibody and strepavidin-horseradish peroxidase complex according to the recommendations of the provider (Histomouse-SP kit, Zymed Laboratories, South San Francisco, CA). Sections were counterstained with hematoxylin.
